The transaction closed on 23 December 2010. The equity capital for the acquisition came from Behrman Capital IV L.P, with debt financing provided by MidCap Financial.
Robert Flaherty, an operating partner at Behrman Capital, will serve as chairman of the Board of Directors at Atherotech.
Developed by Jere Segrest, director of the Atherosclerosis Research Unit at the University of Alabama, Birmingham, Atherotech’s patented VAP Test provides direct, detailed measurements of the lipid subclasses that cause cardiovascular disease.
Behrman Capital managing partner said Grant Behrman said Atherotech’s VAP Test is the premium offering in advanced cholesterol testing and has been steadily gaining higher adoption amongst physicians.
"We look forward to partnering with CEO Mike Mullen and the rest of the Atherotech management team as they continue to pursue the growth of their business," Behrman said.
